Guggenheim 3rd Annual Healthcare Innovation Conference - SEPTERNA INC

Explicit Guidance:

• Clinical Milestones: Anticipates Phase 1 data readout for SEP479 (hyperparathyroidism) in Q1 2027.
• Clinical Milestones: Anticipates initiation of clinical trials for SEP204 (Graves' disease) in Q1 2027.
• Financial Runway: Reported $565 million in cash at end of Q3; funds projected to extend through at least mid-2029, covering the entire pipeline including milestone payments from the Novo collaboration excluded from this count.
• Trial Design Expectations: Anticipates transitioning directly from Phase 1 to Phase 2 in the second half of 2027, contingent on completing chronic toxicology studies prior to patient dosing.

Business-Segment Outlook:

• SEP479 (Hyperparathyroidism): Targeting full-day coverage with a half-life of 3–4 days to minimize peak-to-trough variability; aims to treat moderate patients currently on calcium/vitamin D, potentially expanding the treatable population beyond severe cases requiring injectables (e.g., Urovipath).
• SEP204 (Graves' & Thyroid Eye Disease): Positioning as a once-daily oral small molecule intended to address both thyroid dysfunction and thyroid eye disease (TED) via the TSH receptor; preclinical data suggests potential for dose titration to either normalize thyroid hormones or achieve full suppression.
• SEP631 (Osteoporosis/Natural Product): Advancing a short-acting oral PTH receptor agonist for osteoporosis, leveraging the SABR initiative's new bone mineral density endpoints to accelerate development.
• Novo Collaboration: Managing a portfolio of five targets (four concurrent programs) that are "off the races" and progressing well; includes an inquiry into incretin receptors where small molecule activators aim to replace peptide therapies.

Market and Competitive Outlook:

• Hyperparathyroidism: Anticipates that all patients should receive PTH hormone replacement rather than just calcium/vitamin D; seeks to capture the "moderate" patient segment suffering from symptom burden and high pill burdens, currently underserved by daily injectables.
• Thyroid Disease: Identifies significant unmet need in Graves' disease among patients intolerant to or relapsing on antithyroid drugs (ATDs) or those with concurrent mild TED, a demographic currently not fully addressed by standard care (e.g., TPEZA for severe TED).
• Osteoporosis: Targets a massive unmet need for oral anabolic agents, noting that many patients remain untreated; differentiates via a "pulsatile" short-acting mechanism compared to existing therapies.
• Competitive Advantage: Emphasizes the difficulty historically faced in developing small molecule activators for peptide GPCRs (PTH) and allosteric modulators (TSHR), positioning Septerna's platform as a solution to replace injectable peptides or antibodies with oral therapies.

Macro / Industry Outlook:

• Regulatory/Market Dynamics: Cites the SABR initiative as a structural change in the osteoporosis space that redefined endpoints, enabling rapid development of bone mineral density-based therapies.
• Treatment Trends: Observes a market shift toward oral delivery of previously injectable biologics (e.g., oral incretins), suggesting a broader trend where oral PTH products could become preferred across the board for convenience and patient adherence.
• Long-term Therapy: Highlights the lifelong nature of hypoparathyroidism treatment (40+ years of therapy), creating a compounding value proposition for durable oral replacements.

Strategic Initiatives:

• Pipeline Expansion: Developing a second osteoporosis approach distinct from the hyperparathyroidism program, specifically requiring a short-acting agonist profile.
• Clinical Progression: Planning to utilize an open-label extension study for Phase 2 responders, with the potential to run indefinitely (52–108+ weeks) pending safety data.
• Capital Efficiency: Maintaining a lean, capital-efficient structure built from scratch; no immediate M&A or restructuring mentioned, but retaining high optionality on the capital side.
• Collaboration Management: Continuing to advance the Novo partnership while maintaining autonomy over the core pipeline.

Risks and Headwinds to Outlook:

• Clinical Failure: Acknowledges historical difficulty in cracking the PTH receptor with small molecules and the risk of high human dose projections in earlier TSHR compound series (which was resolved for SEP204).
• Safety Limits: In Phase 1 healthy volunteer trials, ethically capped at 0.5 mg/dL increase in serum calcium, requiring higher dosing strategies for patient studies to confirm efficacy without hypercalcemia risk.
• Dosing Complexity: Anticipates the potential need for multiple dose sizes (similar to Urovipath's eight doses) to manage titration in a disease where every patient requires individualized optimal dosing.
• Model Reliability: Dependence on building an accurate quantitative systems pharmacology model to predict dosing and account for inter-individual variability, though early Phase 1 data shows low variability in half-life.

Management Tone on the Future:

• Confidence: High confidence in the platform's ability to solve historically challenging GPCR targets; management describes the pipeline as "substantial" and "exciting."
• Financial Security: Expressed strong confidence in the financial position, noting "excellent optionality" and a "very strong financial position" with runway extending to mid-2029.
• Strategic Clarity: Tone is decisive and focused on immediate execution, anticipating a "busy 2027" with multiple clinical catalysts (Phase 1 readouts and trial initiations).

Miscellaneous:

• Dose Frequency: Projects SEP204 to be a once-daily oral medication in humans, despite twice-daily dosing observed in rat studies.
• Selectivity: SEP204 demonstrates >1,000-fold selectivity for TSHR over reproductive receptors (FSHR, LHR), critical for safety in the female demographic affected by Graves' disease.
• Animal Models: Utilized in-house developed mouse models of thyroid eye disease (proptosis) to demonstrate histological reversal of disease pathology.